v3.26.1
Commitments and Contingencies - Additional Information (Detail)
€ in Millions
 1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Oct. 31, 2025
USD ($)
ft²
Jul. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
ConsecutiveMonth
Feb. 28, 2023
USD ($)
Nov. 30, 2021
USD ($)
Jun. 30, 2026
USD ($)
Mar. 31, 2026
Jun. 30, 2025
USD ($)
Jun. 30, 2026
USD ($)
Jun. 30, 2025
USD ($)
Dec. 31, 2025
USD ($)
Jun. 30, 2026
EUR (€)
Jul. 01, 2013
USD ($)
Commitments And Contingencies [Line Items]                          
Operating Lease Payments           $ 806,000   $ 919,000 $ 1,745,000 $ 1,891,000      
Operating lease costs           $ 698,000   $ 730,000 $ 1,489,000 1,459,000      
Operating lease weighted average discount rate           7.60%     7.60%   7.60% 7.60%  
Financing Liability           $ 103,000,000     $ 103,000,000   $ 103,400,000    
Financing liability - long term           92,497,000     92,497,000   93,092,000    
Financing liability - current           10,486,000     $ 10,486,000   10,328,000    
Supply Agreement expiration period                 Dec. 31, 2034        
Supply Agreement renewal period                 2 years        
Milestone liabilities           2,003,000     $ 2,003,000   2,003,000    
Returns reserve for acquired product [1]           290,000     290,000   291,000    
Milestone payments                   $ 639,000      
Loss on purchase commitments | €                       € 55.2  
Insulin                          
Commitments And Contingencies [Line Items]                          
Loss on purchase commitments           64,100,000     $ 64,100,000   66,000,000    
Tyvaso DPI                          
Commitments And Contingencies [Line Items]                          
Royalty commencement date     Oct. 01, 2023                    
Royalty termination date     Dec. 31, 2042                    
scPharma [Member]                          
Commitments And Contingencies [Line Items]                          
Area of Land | ft² 9,342                        
Operating Lease Payments $ 28,805,000                        
Lease payments, fixed annual increases $ 779,000                        
Pulmatrix, Inc                          
Commitments And Contingencies [Line Items]                          
Lease renewal option   5 years                      
Landlord-funded tenant improvements payable   $ 700,000                      
Landlord-funded tenant improvements payable per month   6,000,000,000                      
Lease monthly payments   $ 101,282                      
Percentage of annual increment on lease   3.00%                      
Casper L L C                          
Commitments And Contingencies [Line Items]                          
Sale price         $ 102,300,000                
Lease initial term         20 years                
Lease renewal options         renewal options of five years                
Lessee,option to extend [true false]         true                
Operating lease costs         $ 9,400,000                
Operating lease weighted average discount rate         9.00%                
Lease, description         The total annual rent under the Lease started at approximately $9.4 million per year, subject to a 50% rent abatement during the first year of the Lease, and will increase annually by (i) 2.5% in the second through fifth year of the Lease and (ii) 3% in the sixth and each subsequent year of the Lease, including any renewal term, utilizing a weighted average discount rate of 9.0%.                
Security deposit         $ 2,000,000.0                
Lease repurchase description         the Company has four options to repurchase the Property, in 2026, 2031, 2036 and 2041, for the greater of (i) $102.3 million or (ii) the fair market value of the Property.                
Minimum | Casper L L C                          
Commitments And Contingencies [Line Items]                          
Lease repurchase, amount         $ 102,300,000                
Royalty Liability                          
Commitments And Contingencies [Line Items]                          
Effective interest rate                 1.20%        
Deerfield | Milestone Rights Liability                          
Commitments And Contingencies [Line Items]                          
Contingent liability for milestone payments           45,000,000     $ 45,000,000        
Remaining milestone rights liability           2,500,000     2,500,000        
Milestone rights liability, current           500,000     500,000        
Milestone liabilities           2,000,000     2,000,000        
Deerfield | Milestone Rights Liability | Afrezza                          
Commitments And Contingencies [Line Items]                          
Contingent liability for milestone payments           5,000,000     5,000,000        
Milestone rights interest expense recognized           $ 4,500,000              
Deerfield | Milestone Rights Liability | Maximum                          
Commitments And Contingencies [Line Items]                          
Contingent liability for milestone payments                         $ 90,000,000
Russell Ranch Road II LLC | Office Lease                          
Commitments And Contingencies [Line Items]                          
Operating lease rent expenses       $ 79,543                  
Percentage of annual increase in lease payment       3.00%                  
Description of right to extension of lease term             The Company has no further right to extend the lease term beyond July 31, 2028.            
Russell Ranch Road II LLC | Maximum | Office Lease                          
Commitments And Contingencies [Line Items]                          
Reimbursement for tenant improvements       $ 900,000                  
Additional base rent concession       $ 700,000                  
Sagard                          
Commitments And Contingencies [Line Items]                          
Upfront proceeds     $ 150,000,000                    
Reimbursements     $ 400,000                    
Percentage of royalty on future net sales     1.00%                    
Unamortized transaction costs                 $ 3,800,000   $ 3,900,000    
Sagard | Tyvaso DPI                          
Commitments And Contingencies [Line Items]                          
Purchase price     $ 200,000,000                    
Sagard | Net Sales Threshold A | Tyvaso DPI                          
Commitments And Contingencies [Line Items]                          
Milestone payments     50,000,000                    
Net sales     $ 1,900,000,000                    
Number of consecutive months | ConsecutiveMonth     12                    
Sagard | Net Sales Threshold B | Tyvaso DPI                          
Commitments And Contingencies [Line Items]                          
Milestone payments     $ 45,000,000                    
Net sales     $ 2,300,000,000                    
Number of consecutive months | ConsecutiveMonth     12                    
Sagard | Net Sales Thresholds A and B | Tyvaso DPI                          
Commitments And Contingencies [Line Items]                          
Net sales     $ 3,500,000,000                    
Sagard | Remainder of Year                          
Commitments And Contingencies [Line Items]                          
Royalties     $ 0                    
Sagard | Royalty Liability                          
Commitments And Contingencies [Line Items]                          
Royalty rights     1.00%                    
Transaction costs     $ 4,400,000                    
Percentage of Future Royalty Revenues     10.00%                    
[1] See Note 15 – Commitments and Contingencies under Loss Contingencies — Returns Reserve for Acquired Product.